Drug news
Avastin (Roche) success in Cervical Cancer trial
The National Institutes of Health (Gynaecological Oncology Group) revealed data showing that Avastin (bevacizumab) from Genentech/Roche, produced a median survival benefit of 17 months in the GOC 240 trial in patients with Cervical Cancer, compared to 13.3 months in the chemotherapy arm of the trial.
Roche provided the drug but was not involved in the trial itself. Full data will be released at the meeting of the American Society of Clinical Oncology.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.